Sandra Elaine Dunn, Hung T. Khong, Muralidhar Beeram, Robert Wesolowski, Hyo S. Han, Nicolaos Jay Palaskas, Aarthi Jayanthan, Martin Sebastian Olivo, Brian Barnett. "Dauntless-1, a phase 2 clinical trial to evaluate PMD-026, a first-in-class pan-RSK inhibitor, combined with fulvestrant to overcome resistance to CDK4/6 inhibitors in advanced or metastatic HR+/HER2- breast cancer.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.tps1130